Loading
Aarti Pharmalabs Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Hetal Gogri Gala, was filed 04 Dec 2025.
Insider Decl.
71
Thresholds
n/a
Buy Volume
€6M
16 ops. · all time
Sell Volume
€36M
52 ops. · all time
Who traded when
BuySaleTulip Family Trust11 sales
Safechem Enterprises Private Limited10 sales
Orchid Family Trust9 sales
Nikhil Parimal Desai5 sales
ORCHID FAMILY TRUST (Relacion Trusteeship Services Private Limited)4 sales
Narendra J Salvi3 sales
+9 other insiders
Since the insiders bought
- +16.9%Entry ₹721.55 · Close 21 Oct 2026 ₹843.25
- -1.1%Entry ₹718.85 · Close at T+365 ₹710.80
- +69.7%Entry ₹298.45 · Close at T+365 ₹506.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,455 of 26,280 companies
46.2
score / 100
Value32
Quality61
FCF yld-2.5%
Earn yld2.3%
EV/EBITDA21.4x
ROE8.5%
Gross mgn44%
Net mgn9.8%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹840.05
Analyst consensus
1 analysts3.00/5
₹740.00Target ₹740.00(-12%)₹740.00
Income statement
Revenue₹17.9B
Gross profit₹7.9B44% margin
EBITDA₹3.8B21% margin
Net income₹1.7B10.4% margin
Valuation
PER (trailing)35.7x
PER (forward)32.9x
P/Book3.6x
Beta0.26
Balance sheet & cash
Market cap₹76.2B
Total debt₹7.7B
Free Cash Flow-₹1.9B
Debt / Equity37%
Profitability & ownership
ROE8.5%
ROA5.8%
% insiders44.0%
% institutions12.4%
Last declaration on 25 September 2026
Declarations71 total
380,000 shares@ ₹818.800.38% mcap35.6% of flowEquityMarket SaleSEBI:a6aa0c63e7b1aa996276dc5eef161f36a87b34d5
388,725 shares@ ₹818.800.39% mcap100.0% of flowEquityMarket SaleSEBI:29b8c96b0f3a43a970cf537f4da0ff390fcc0ce7
397,500 shares@ ₹818.800.40% mcap39.0% of flowEquityMarket SaleSEBI:539a388fc28d04f499c7d87caee6679cf6e30a16
133,564 shares@ ₹818.800.13% mcap100.0% of flowEquityMarket SaleSEBI:b94f4f72edc5bee7cd5e0564f34994a1121b170a
627,500 shares@ ₹818.800.63% mcap58.5% of flowEquityMarket SaleSEBI:3785c46069d1f253c336fbb01fa49aca450f0dcb
624,500 shares@ ₹818.800.63% mcap61.0% of flowEquityMarket SaleSEBI:c3d32e2a0e9ff82cdbab13c322202acb2b52b696
60,000 shares@ ₹871.100.066% mcap5.9% of flowEquityMarket SaleSEBI:8d9d7db996db27726f62ef8ba60ff62249e724b0
59,400 shares@ ₹875.200.066% mcap19.5% of flowEquityMarket SaleSEBI:eba522d7ef3f3d9195b23bc4e334a657927c2454
30,000 shares@ ₹864.400.030% mcap9.8% of flowEquityMarket SaleSEBI:c828911928fa1ffb82c498ec3d2b7c0e68ce51fa
600 shares@ ₹853.100.0006% mcap0.2% of flowEquityMarket SaleSEBI:b448819725659df19e7172dc16e16fcb22ba6a0c
15,000 shares@ ₹878.700.015% mcap4.9% of flowEquityMarket SaleSEBI:a6714ce276b7d1a9ae7560bc567ab621efb7b0aa
10,000 shares@ ₹868.300.0100% mcap66.3% of flowEquityMarket SaleSEBI:5277b01eba90c25c87f2f4bd67fe9933b047ea98
5,000 shares@ ₹881.800.0051% mcap33.7% of flowEquityMarket SaleSEBI:f915bf0d8592ae72b4aaea728d8d1b76bf9b3a3e
55,000 shares@ ₹859.900.054% mcap17.7% of flowEquityMarket SaleSEBI:eafd1ec84431c73cd25f7c8661bd6ff296abecef
23,482 shares@ ₹881.800.024% mcap7.8% of flowEquityMarket SaleSEBI:c6ab0cdd5a6743376f49f6792e48c80dcb7eb1cc
88,268 shares@ ₹682.700.070% mcap22.9% of flowEquityMarket SaleSEBI:cdb73f46993cd672e510636cb7c6f594890546c4
65,000 shares@ ₹686.900.053% mcap17.1% of flowEquity SharesMarket SaleSEBI:571b49aaf77a47e91f226f2952078f49823c1245
9,000 shares@ ₹705.7331100.0% of flowEquity SharesSEBI:670f1939980b71e4317c67fa510b04e662525838
3,000 shares@ ₹722.114315.1% of flowEquity SharesSEBI:983cfe7fae2ee45e66d735a1bcedb136af486151
63,769 shares@ ₹700.196899.9% of flowEquity SharesSEBI:882f4d6bc36764f847d0b5594647d7e74fc8f613
Canonical exit: 2 Mar 2026 (T+90)
64 shares@ ₹687.56250.1% of flowEquity SharesSEBI:2d9e99ca5651d710eb4590f2a768806a7f7768cb
Canonical exit: 3 Mar 2026 (T+90)
●
-
0SEBI
5,000 shares@ ₹881.238443.4% of flowEquity SharesSEBI:18224f15e0e947109e232cdbcc44f6085ae12574
600,000 shares@ ₹928.26295.3% of flowEquity SharesSEBI:0a8be28de84e5a0e700da94e8c5a0d9155f45b51
30,000 shares@ ₹913.91634.7% of flowEquity SharesSEBI:3b743bdf19fe353f40616ec5763b133092af2b2c
25 of 71 declarations
About Aarti Pharmalabs Limited
Sales dominate the record of Aarti Pharmalabs Limited: 52 sales for EUR 35,856,830 (median EUR 268,162), against 16 purchases for EUR 5,980,461, or 24% purchases among open-market trades. The largest sale, EUR 5,354,029, is by Safechem Enterprises Private Limited, on September 19, 2025. On September 22, 2026, two neighbouring sales come in at EUR 4,675,480 (Relacion Trusteeship Services Private Limited) and EUR 4,653,351 (Gloire Trusteeship Services Private Limited), both under the entry Promoter Group.
The purchases are concentrated in February 2023: between February 7 and February 10, 2023, five distinct filers bought for EUR 5,386,664, including EUR 1,312,697 for Anushakti Enterprises Pvt Limited on February 7, 2023 and two purchases by Manomaya Business Trust (Alabhya Trusteeship Private Limited), EUR 801,707 on February 9, 2023 and EUR 795,318 on February 10, 2023.
Read moreShow less
An Indian health care and pharma company with a market capitalisation of INR 76.2 billion, it has 71 filings from 23 filers, covering trades from February 7, 2023 to September 25, 2026, 40 of them in 2025. Filings are published a median of one day after the trade. For 16 purchases a 90-day result is stored: a median of 25%, with 88% of results positive, recorded past results, not a forecast.
